The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon
REMFRY HOUSE AT THE MILLENNIUM PLAZA, SECTOR 27, GURGAON - 122 009, INDIA
Tel:
Work +91-124-280-6100
Fax:
Fax +91 12 4280 6101
Email:
Web:
www.remfry.com

Top-tier Firm rankings


India

Intellectual property
Intellectual property - ranked: tier 1

Remfry & Sagar

IP boutique Remfry & Sagar is led by Ashwin Julka, and counts Diageo, AstraZeneca, Google and LG Display among its clients. The team has notable strengths in the pharmaceuticals sector and represented Beckman Coulter Biomedical before the Madras High Court in a dispute with the Patent Office. Other highlights include advising Costco Wholesale on a trade mark infringement claim and acting for Quixey in a domain name issue before the National Internet Exchange of India’s .in registry. Vishnumohan Rethinam, Vineet Rohilla and Samta Mehra are also recommended.

Leading individuals

Ashwin Julka - Remfry & Sagar

[back to top]


Further information on Remfry & Sagar

Please choose from this list to view details of what we say about Remfry & Sagar in other jurisdictions.

India

Offices in Gurgaon

Legal Developments in India

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Chambers Guides - Insurance 2018 - India

    India is a common-law jurisdiction. In general, Indian laws borrow heavily from, and are based on, English law. However, insurance law in India has certain unique features that deviate from English insurance law. The primary legislation of insurance law in India is the Insurance Act, 1938 (the “Insurance Act”) and the Insurance Rules, 1939 (the “Insurance Rules”).
  • Transport Finance Review - India

    The transportation industry – aviation, shipping and rail – has been predominantly owned by government entities since India’s independence in 1947. Air India and Indian Airlines, both government-owned, rules the skies; the Shipping Corporation of India (SCI), established in 1961 and owned by the government, owns and operates around one-third of the Indian tonnage. All railway property is government owned.
  • International Arbitration Review - India

    The Arbitration and Conciliation Act, 1996 (Act) provides the framework for arbitration and conciliation in India. Drafted on the basis of the UNCITRAL Model Law, it is divided into four parts. Each part governs a different aspect of the arbitration and conciliation process: a Part 1 governs commercial arbitration; b Part 2 governs the enforcement of certain foreign awards; c Part 3 governs conciliation; and d Part 4 contains supplementary provisions (regarding the power of the court to make rulings, etc.). The Act 2 was recently amended in 2016 with an aim to make it more robust by plugging the lacunae that existed in the original legislation.
  • ICLG Shipping law 2018 - India

    In the event of a collision, grounding or other major casualty, what are the key provisions that will impact upon the liability and response of interested parties? In particular, the relevant law / conventions in force in relation to:
  • India - Chambers Guides - Shipping 2018

    The ‘Law & Practice’ sections provide easily accessible information on navigating the legal system when conducting business in the jurisdiction. Leading lawyers explain local law and practice at key transactional stages and for crucial aspects of doing business.
  • BRAND-JACKING

    WHAT IS BRANDJACKING?
  • Post Marketing Surveillance of Drugs

    Post marketing surveillance is performed after market approval/clinical trials of drugs in India. The regulatory framework for conducting clinical trials of drugs is provided under the Drugs and Cosmetics Act, 1940 (“ Act ”) and the Drugs and Cosmetics Rules, 1945 (“ Rules ”). Further, Part X-A and Schedule Y of the Rules specifically deal with the statutory provisions applicable for clinical trial of drugs in India. Schedule Y divides Clinical trial of drugs into 4 Phases, namely, Human Pharmacology (Phase-I), Therapeutic exploratory trials (Phase-II), Therapeutic confirmatory trials (Phase III) and Post Marketing Trials (Phase-IV).
  • Protection of Biotechnology under Indian Laws

    According to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and Bio Spectrum, the Indian biotech industry grew threefold in just five years to report revenues of US$ 3 billion in 2009-10, a rise of 17 per cent over the previous year. Maintaining the momentum of the previous years, the Indian biotech industry grew 16.28 per cent in FY2014; the total industry size was US$ 5 billion at the end of the financial year and it reached US$ 7 billion in FY2015. Fast-paced growth is likely to continue; the industry is expected to increase in size to USD11.6 billion by 2017, driven by a range   of factors such as growing demand, intensive R & D activities and strong government initiatives ( http://www.ibef.org/industry/biotechnology-india.aspx )
  • Cabinet Approves India’s IPR Policy - “Creative India; Innovative India: रचनात्म??

    The Union Cabinet on 13 May 2016 approved the National Intellectual Property Right (IPR) policy roadmap ( http://dipp.gov.in/English/Schemes/Intellectual_Property_Rights/National_IPR_Policy_12.05.2016.pdf ) to foster creativity and innovation, promote entrepreneurship and enhance socio development, enhance access to healthcare, food security and environmental protection. The Policy recognizes the abundance of creative and innovative energies that flow in India, and the need to tap into and channelize these energies towards a better and brighter future for all.
  • Real Estate - India

    Real Estate - India